Reported net income rose 30% to $5 billion, or $0.89 per
share, compared to the prior-year quarter. Adjusted income decreased 2% to $4.5
billion while adjusted EPS rose 4% to $0.80, beating forecasts of $0.75.
During the quarter, revenue in the Biopharma business grew 2%
to $9.6 billion, driven by growth in key brands such as Ibrance, Xeljanz and
Eliquis. The growth was partially offset by lower revenues from Enbrel and
Prevnar 13. Revenues in the Upjohn segment fell 11% to $2.8 billion, hurt by
declines in the US and China. Consumer Healthcare segment revenues fell 3% to $862
million.
Pfizer updated its guidance for fiscal year 2019 to reflect the
formation of its JV with GlaxoSmithKline plc and the expected completion of the
Array BioPharma acquisition. The company now expects revenues of $50.5-52.5
billion versus the prior outlook of $52-54 billion. Adjusted EPS is estimated to
be $2.76-2.86 compared to the previous range of $2.83-2.93.
Pfizer also announced an agreement to combine its Upjohn
business with Mylan NV (NASDAQ: MYL), creating a new global pharmaceutical
company. The agreement is structured as an all-stock, Reverse Morris Trust transaction
and is expected to close in mid-2020. Pfizer’s shareholders will own 57% of the
combined company and Mylan’s shareholders will own 43%.
Michael Goettler will be the Chief
Executive Officer of the new entity. The new company is expected to have pro
forma 2020 revenues of $19-20 billion. Pro forma 2020 adjusted EBITDA is
estimated to be $7.5-8.0 billion, including phased synergies of approx. $1
billion annually to be realized by 2023. Pro forma free cash flow for 2020 is
expected to be more than $4 billion.
Pro forma for the separation of the Upjohn business, Pfizer expects to generate 2020 revenues of approx. $40 billion.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.